GB Sciences Signs Licensing Deal with Endopure Life Sciences for Cannabinoid-Based Neurological Treatments

GB Sciences, Inc., a biopharmaceutical research and development company, has signed a letter of intent to license its cannabinoid-based treatments for neurological disorders to Endopure Life Sciences, LLC. This deal will cover markets in Brazil and South America. Endopure Life Sciences is experienced in providing cannabinoid-based medicines in these regions.

Aging populations have increased the demand for neurological disorder treatments, including Parkinson's and Alzheimer's diseases. The global market for these treatments is projected to reach $6.42 billion USD by 2032. GB Sciences' formulations aim to address this growing market.

The licensing deal will provide GB Sciences with royalties and capital to support first-in-human trials in Brazil and South America. These trials will generate data to aid GB Sciences' efforts for U.S. FDA approvals. Expedited regulatory pathways in these regions allow for valuable post-market data gathering.